This beneficial effect was associated with (1) reduction in oxidative DNA damage, (2) decrease in BBB leakage in the hippocampus, and (3) suppression of MMP-9 activity in the hippocampus at 8 weeks after treatment (14 weeks of age; before stroke onset). The gene discussed is MMP9; the disease is Stroke.